Prof. Yong Ha Park: The Scientific Force Behind Probionic Corp’s Strain-Level Innovation


15th Asian Conference on Lactic Acid Bacteria (ACLAB 2025)
Theme: “Roles of Lactic Acid Bacteria: From Traditional Applications to an Innovative Future”
📍Taipei, Taiwan | 📅 November 19–21, 2025

A Spotlight on South Korea’s Microbiome LeadershipAt ACLAB 2025, one name stood out not just as a speaker — but as a symbol of South Korea’s rise in global microbiome research: Prof. Yong Ha Park, Founder and CEO of Probionic Corp.

​
Invited to speak under the headline “Kimchi to Drug”, Prof. Park captivated researchers, clinicians, and biotech developers with a narrative only he could tell — a story that bridges Korea’s rich fermentation heritage with next‑generation therapeutic probiotics. His role as a special invited speaker reflects recognition of his more than 30 years of pioneering research in skin microbiome science and his groundbreaking work in translating kimchi fermentation into clinically validated probiotic innovation.
From Kimchi to Drug: Korean Fermentation Meets Modern TherapeuticsIn his invited session, Prof. Park presented new research and clinical insights into Lactobacillus sakei Probio65®, Probionic’s patented probiotic strain originally isolated from traditional Korean kimchi.

Key findings highlighted include:

• Reinforcing the skin barrier and improving atopic dermatitis
• Natural anti-inflammatory and antimicrobial activity
• Supporting sinus and nasal comfort through microbiome balance
• Enhancing gut microbiota diversity and resilience
• Regulating immune activity in hypersensitive conditions
  
  

With growing clinical evidence and multiple global patents, Probio65® is now incorporated into nutraceuticals, cosmeceuticals, functional foods, and veterinary health formulations worldwide.
Showcasing South Korea’s Expertise on the Global StageProf. Park’s invitation underscores Asia’s expanding interest in South Korea’s rapid advancements in strain‑specific probiotic development. His work demonstrates how traditional fermentation science can be transformed into evidence‑based therapeutic platforms, inspiring researchers and industry leaders alike.
The response at ACLAB 2025 was strong, reflecting rising demand for microbiome‑targeted solutions in skin disorders, sinus health, and immune modulation.

Industry Impact: Strengthening K‑Biotech and Global CollaborationAs the global market shifts toward clinically validated, science‑backed probiotic strains, Prof. Park’s work continues to attract interest from:

• International pharmaceutical and nutraceutical developers
• Dermatology and skin microbiome brands
• Veterinary and pet‑health formulators
• Academic and clinical microbiome research groups
  
  

Probionic Corp. is expanding its global footprint through OEM manufacturing, private‑label development, ingredient partnerships, and advanced microbiome R&D — reinforcing Korea’s position at the forefront of the probiotic ingredient industry.

Watch the Official The full invited lecture by Prof. Yong Ha Park at ACLAB 2025 is now available online:
📽YouTube : https://www.youtube.com/watch?v=JA6Dy8UJsGM
​